Related Experiment Video
Updated: Jul 18, 2026
06:35
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Glatiramer acetate therapy for multiple sclerosis: a review
Jai Perumal1, Massimo Filippi, Corey Ford
1Wayne State University School of Medicine, Department of Neurology, 8D-UHC, Detroit, MI 48201, USA.
Expert Opinion on Drug Metabolism & Toxicology
|November 28, 2006
Summary
Glatiramer acetate (GA) is an effective treatment for relapsing-remitting multiple sclerosis (MS), reducing relapses and disability for at least 10 years. GA also demonstrates neuroprotective effects and a favorable safety profile.
Area of Science:
- Neuroimmunology
- Demyelinating Diseases
- Pharmacology
Background:
- Multiple sclerosis (MS) is a leading cause of neurological disability.
- Historically considered untreatable, MS now has several disease-modifying therapies.
- Glatiramer acetate (GA) is a key treatment approved for relapsing-remitting MS.
Purpose of the Study:
- To review the efficacy and mechanisms of glatiramer acetate in multiple sclerosis.
- To highlight the long-term benefits and safety of GA.
- To explore the neuroprotective potential of GA.
Main Methods:
- Review of placebo-controlled trials and long-term observational studies.
- Analysis of immunological mechanisms of action.
- Evaluation of neuroimaging data on axonal injury.
Main Results:
- GA significantly reduces relapse rates and neurological disability in relapsing-remitting MS.
- Long-term studies show sustained efficacy of GA over 10 years.
- GA induces anti-inflammatory T-helper 2 lymphocytes and exhibits neuroprotective properties.
Conclusions:
- Glatiramer acetate is a safe and effective first-line treatment for relapsing-remitting MS.
- GA's sustained efficacy, safety, and neuroprotective effects support its role in MS management.
- GA holds promise for combination therapy and treatment of other neurodegenerative diseases.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...